Venetoclax Add-On Improves Complete Remission in AML : vimar

A phase 2 study found 91% complete remission in patients with AML who received venetoclax plus standard therapy. The study was published as a preprint and has not yet been peer reviewed.

Related Keywords

China , Zhejiang , Huafeng Wang , Entrepreneur Team Introduction Program Of Zhejiang , National Natural Science Foundation Of China , Zhejiang University School Of Medicine , European Leukemianet , Leading Innovative , Entrepreneur Team Introduction Program , National Natural Science Foundation , First Line Therapy , Adult Patients With Acute Myeloid Leukemia , Zhejiang University School , Acute Leukemia , Acute Myeloblastic Leukemia , Hematology , Chemotherapy , Physician Assistants , Anthracyclines , Neoadjuvant , Peer Review , Young Adult ,